- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07694583
Evaluating the Efficacy of a Tocotrienols-Loaded Dressing in Wound Care for Pressure Ulcers (TOCOWO)
A Prospective, Double-Blinded, Randomized Controlled Trial to Evaluate the Efficacy of a Formulated Dressing Containing Tocotrienols in Wound Care for Pressure Ulcers
The goal of this clinical trial is to investigate the effects of the dressing containing Tocotrienols on patients with stage 1 and stage 2 pressure ulcers. The main questions it aims to answer are:
- Will the dressing containing Tocotrienols lead to a reduction in the Pressure Ulcer Scale for Healing (PUSH) Score?
- Will the dressing containing Tocotrienols help heal the participants' pressure ulcer wounds?
- Will the dressing containing Tocotrienols lead to reduction in wound surface area?
- What is the percentage of patients with completely healed wounds by the end of the study?
Researchers will compare Tocotrienols-loaded formulated dressing to conventional dressing (standard of care as control) in pressure ulcers.
Participants will:
- Have their pressure ulcers checked by a study doctor to ensure they are infection-free and suitable ulcer fitting the inclusion criteria
- Undergo 24-hour allergy testing with patch of Tocotrienol-loaded dressing and standard hydrocolloid dressing
- Be randomly assigned to one of three groups if they qualify: control, vehicle-control, or treatment group
- Assess skin sensitivity testing the next day, and if qualify, will be started on first dosing.
- Attend follow-up visits on days 1, 3, 5, 7, 15, 22, 29, 35 and 43, where additional questions and assessments will be completed.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
The purpose of this study is to investigate the effects of the dressing containing Tocotrienols on patients with pressure ulcers. This research is necessary because pressure ulcers is common in patient with critical illness and bedbound. Therefore, proper wound care management is crucial. Tocotrienols has been proven to have numerous health benefits, and in this study, its use will be investigated for pressure ulcers in human subjects. A total of 114 participants from patients admitted to UMMC (University Malaya Medical Centre) will be participating in this study. The whole study will last about 3 years and each participant will last about 43 days or 6 weeks.
This study is important because it is hypothesised that the Tocotrienols-loaded wound dressing will be able to reduce wound complications on application through its anti-inflammatory, anti-oxidant and wound healing effects, and provide better wound care outcome. This study also provides fundamental groundwork to expand the use of Tocotrienols in surgical and non-surgical wound management, as well as scar reduction in aesthetic and cosmetic applications.
The participants that are invited to participate in the research study because they have pressure ulcers that requires Tocotrienols-loaded formulated dressing. Participants should not take part in this study if they have multiple known allergies to various types of dressings, if their wound is determined to be infected, or if there are of skin necrosis requires special dressing and topical antibiotic treatment. Additionally, individuals with any medical conditions that, in the investigator's opinion, could potentially compromise their safety, adherence, or ability to successfully complete the clinical trial will also be excluded from participation.
This is a double-blinded randomized controlled trial. The procedure that is being tested is a Tocotrienols-loaded formulated dressing on Stage 1 and Stage 2 pressure ulcers. The participants will be randomly assigned to one of the treatment groups below:
Group 1: Tocotrienols-loaded formulated dressing Group 2: Conventional hydrocolloid dressing (standard of care as control) Neither the participants nor the doctor will know which group the participants are assigned to but in the case of emergencies, this information will be available to the doctor.
During the length of the study, the participants involvement will include:
- Being screened by the study doctor, who will examine their pressure ulcers and recruit them if they are eligible.
- If eligible, they will be randomly assigned to either the control or treatment group.
- Undergo 24-hour allergy testing with patch of Tocotrienol-loaded dressing and standard hydrocolloid dressing
- Assess skin sensitivity testing the next day, and if qualify, will be started on first dosing.
- Attend follow-up visits on days 3, 5, 7, 15, 22, 29, 35 and 43, where additional questions and assessments will be completed.
This study is sponsored by the Malaysian Palm Oil Board (MPOB) who will pay for all study products and procedures. All the information obtained in this study will be kept and handled in a confidential manner, in accordance with applicable laws and/or regulations. Data from the study may be archived for the purpose of analysis, but the participants' identity will not be revealed at any time.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Lay Hong Dr. Chuah, PHD, MPharm, R.Ph
- Numer telefonu: +6017-3592799
- E-mail: alice.chuah@monash.edu
Lokalizacje studiów
-
-
Selangor
-
Kuala Lumpur, Selangor, Malezja, 59100
- Rekrutacyjny
- University Malaya Medical Centre
-
Kontakt:
- Dr Hannis
- Numer telefonu: +60134284092
- E-mail: hannis.arbaie@ummc.edu.my
-
Główny śledczy:
- Kah Seng Dr. Khoo, MBBS, MRCS, MS
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- The included participants or caretakers are older than 18 years with at least one pressure ulcer that was stage I-II as classified by the National Pressure Ulcer Advisory Panel and the European Pressure Ulcer Advisory Panel (NPUAP/EPUAP)
- Exhibited a pressure ulcer surface area of <80 cm2 (multiplication of the major and minor diameters of the wound surface)
- PUSH (version 3.0) score of >5 that was likely to heal during the 6-month study period
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
Exclusion Criteria:
- Stage III & IV pressure ulcers requiring different standard of care
- Multiple known allergies to other types of dressings
- Wound deemed to have an infection
- Area of skin necrosis that requires special dressing and/or topical antibiotic treatment
- Any (medical) conditions that would, in the opinion of the investigator, potentially compromise the safety or compliance of the subject or may preclude the subjects' successful completion of the clinical trial
- Allergic to dressings during 24-hour pre-study allergy test
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Tocotrienol dressing
Participants in this experimental arm will receive a Tocotrienol-loaded dressing.
The dressing will be applied topically to the affected area, and the treatment will continue for a duration of 6 weeks.
|
Tocotrienol-loaded formulated dressing is designed as all-in-one easy to use dressing.
This is the first dressing formulated to contain tocotrienols.
The dressing is expected to speed up the healing process compared to control.
|
|
Komparator placebo: Conventional dressing
Participants in this experimental arm will receive a conventional dressing as standard care (control).
The dressing will be applied topically to the affected area, and the treatment will continue for a duration of 6 weeks.
|
The standard care serves as a control, using a conventional hydrocolloid dressing.
This control group allows for a comparison with the intervention to assess differences in outcomes at the end of the study.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Reduction in Pressure Ulcer Scale for Healing (PUSH) score
Ramy czasowe: Day 0, Day 1, Day 3, Day 5, Day 7, Day 15, Day 22, Day 29, Day 35, Day 43
|
This primary outcome measure was developed by The National Pressure Ulcer Advisory Panel to monitor pressure healing over time.
The range of the score is 0-17, that is, from completely healed to the greatest severity.
The scale consists of 3 domains: length times width (10-scale), exudate amount (none, light, moderate, and heavy), and tissue type (necrotic tissue, slough, granulation tissue, epithelial tissue and closed wound).
|
Day 0, Day 1, Day 3, Day 5, Day 7, Day 15, Day 22, Day 29, Day 35, Day 43
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Reduction in wound area
Ramy czasowe: Day 0, Day 1, Day 3, Day 5, Day 7, Day 15, Day 22, Day 29, Day 35, Day 43
|
This secondary outcome measure was chosen because a greater reduction in wound area would indicate faster healing.
|
Day 0, Day 1, Day 3, Day 5, Day 7, Day 15, Day 22, Day 29, Day 35, Day 43
|
|
Percentage of patients with completely healed wound
Ramy czasowe: Day 0, Day 1, Day 3, Day 5, Day 7, Day 15, Day 22, Day 29, Day 35, Day 43
|
This secondary outcome measure provides an indication of the wound healing rate throughout the study.
|
Day 0, Day 1, Day 3, Day 5, Day 7, Day 15, Day 22, Day 29, Day 35, Day 43
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Publikacje ogólne
- Guo HF, Mohd Ali R, Abd Hamid R, Chang SK, Rahman MH, Zainal Z, Khaza'ai H. Epidermal Growth Factor and Tocotrienol-Rich Fraction Cream Formulation Accelerates Burn Healing Process Based on Its Gene Expression Pattern in Deep Partial-Thickness Burn Wound Model. Int J Low Extrem Wounds. 2022 Dec;21(4):544-554. doi: 10.1177/1534734620971066. Epub 2020 Nov 26.
- Guo HF, Abd Hamid R, Mohd Ali R, Chang SK, Rahman MH, Zainal Z, Khaza'ai H. Healing Properties of Epidermal Growth Factor and Tocotrienol-Rich Fraction in Deep Partial-Thickness Experimental Burn Wounds. Antioxidants (Basel). 2020 Feb 3;9(2):130. doi: 10.3390/antiox9020130.
- Ruiz-Tovar J, Llavero C, Perez-Lopez M, Garcia-Marin A. Effects of the application of vitamin E and silicone dressings vs conventional dressings on incisional surgical site infection in elective laparoscopic colorectal surgery: a prospective randomized clinical trial. J Hosp Infect. 2019 Jul;102(3):262-266. doi: 10.1016/j.jhin.2018.10.021. Epub 2018 Nov 3.
- Alias D, Ruiz-Tovar J, Moreno A, Manso B, Diaz G, Duran M, Garcia-Olmo D. Effect of Subcutaneous Sterile Vitamin E Ointment on Incisional Surgical Site Infection after Elective Laparoscopic Colorectal Cancer Surgery. Surg Infect (Larchmt). 2017 Apr;18(3):287-292. doi: 10.1089/sur.2016.199. Epub 2017 Jan 6.
- Lin TS, Abd Latiff A, Abd Hamid NA, Wan Ngah WZ, Mazlan M. Evaluation of topical tocopherol cream on cutaneous wound healing in streptozotocin-induced diabetic rats. Evid Based Complement Alternat Med. 2012;2012:491027. doi: 10.1155/2012/491027. Epub 2012 Oct 14.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- RSCH ID-24-01422-IRV
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Odleżyny Etap II
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktywny, nie rekrutującyKlasyczny chłoniak Hodgkina | Bogaty w limfocyty klasyczny chłoniak Hodgkina | Ann Arbor Stadium IB Chłoniak Hodgkina | Ann Arbor II stadium chłoniaka Hodgkina | Ann Arbor Stadium IIA Chłoniak Hodgkina | Ann Arbor Stadium IIB Chłoniak Hodgkina | Ann Arbor I stopień chłoniaka Hodgkina | Ann Arbor Etap I... i inne warunkiStany Zjednoczone
-
National Cancer Institute (NCI)Aktywny, nie rekrutującyMiędzybłoniak dwufazowy | Międzybłoniak nabłonkowy | Stage I Opłucnowy Rozlany Złośliwy Międzybłoniak AJCC v7 | Międzybłoniak opłucnej złośliwy rozsiany w stadium IA według AJCC v7 | Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7 | Międzybłoniak złośliwy opłucnej w stadium II AJCC v7 | Międzybłoniak...Stany Zjednoczone
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RekrutacyjnyRak płaskonabłonkowy głowy i szyi | STAPOWA IV Głowa i szyja rak płaskonabłonkowy AJCC V8 | STAPII III Głowa i szyja rak płaskonabłonkowy AJCC V8 | Stage I głowa i szyja rak płaskonabłonkowy AJCC V8 | STAPI II Rak płaskonabłonkowy i szyi rak płaskonabłonkowy AJCC V8Stany Zjednoczone
-
NRG OncologyNational Cancer Institute (NCI)RekrutacyjnyZapalenie jamy ustnej | Rak płaskonabłonkowy głowy i szyi | Rak płaskonabłonkowy jamy ustnej i gardła | Stopień kliniczny III zależny od HPV (p16-dodatni) rak jamy ustnej i gardła AJCC v8 | Rak gardła dolnego stopnia III AJCC v8 | Rak krtani stopnia III AJCC v8 | Rak wargi i jamy ustnej III stopnia... i inne warunkiStany Zjednoczone